Hepatic impairment changes psychiatric prescribing in two ways: drugs metabolized by the liver may accumulate to toxic levels, and drugs with hepatotoxic potential become particularly concerning. Whether you're prescribing for a patient with cirrhosis, hepatitis, or drug-induced liver injury, the approach shifts.
- Class
- Hepatic impairment prescribing framework
- Mechanism
- Hepatic dysfunction → reduced CYP activity → reduced clearance of CYP-metabolized drugs → accumulation. Glucuronidation often relatively preserved.
- FDA indications
- All psychiatric disorders in patients with hepatic dysfunction
- Key adverse effects
- Drug-dependent — accumulation, hepatotoxicity (added insult)
Generally safer: agents with predominant renal clearance (gabapentin, paliperidone — but renal function may also be affected); glucuronidated benzodiazepines (lorazepam, oxazepam, temazepam); SSRIs with simpler metabolism (sertraline, escitalopram). Avoid or use cautiously: nefazodone, duloxetine, valproate (hepatotoxic), naltrexone (high-dose), agents with active hepatically-cleared metabolites.
The pathway principle: CYP-mediated oxidative metabolism is impaired in hepatic disease. Glucuronidation — a different metabolic pathway — is relatively preserved. This is why the LOT benzodiazepines (lorazepam, oxazepam, temazepam) are preferred in hepatic impairment: they're glucuronidated only, not CYP-metabolized. Diazepam and chlordiazepoxide, by contrast, undergo extensive CYP metabolism with multiple active metabolites that accumulate dangerously in liver disease.
Hepatic impairment prescribing turns on a single question — does the drug depend on the liver to be cleared — and chooses agents accordingly.
Mechanism note: Hepatic impairment prescribing favors glucuronidated or renally-cleared agents, reduces doses of hepatically-metabolized drugs, and avoids the agents with intrinsic hepatotoxicity.
Safer choices in hepatic impairment: Sertraline and escitalopram (simpler hepatic metabolism than paroxetine or fluvoxamine). Acamprosate for AUD (renal clearance, bypasses liver). Gabapentin and pregabalin (renal clearance). LOT benzodiazepines when BZD is needed. Lithium (renal clearance, though has its own monitoring requirements).
Avoid or use cautiously: Nefazodone — black-box hepatotoxicity, contraindicated in significant hepatic dysfunction. Duloxetine — hepatotoxicity risk, contraindicated in chronic alcohol use or significant liver disease. Valproate — hepatotoxicity especially in patients with cirrhosis or alcohol use. TCAs — extensive hepatic metabolism plus their own cardiac/anticholinergic burden. Carbamazepine — hepatic metabolism plus drug interactions plus potential hepatotoxicity.
Dose adjustment principles: For drugs that must be used despite hepatic impairment, reduce starting dose by 25-50 percent and titrate more slowly. Check LFTs at baseline and periodically. Watch for signs of new hepatic injury — even on agents not previously associated with hepatotoxicity, hepatically impaired patients may be more vulnerable.
The cirrhotic AUD patient is a specific case that comes up frequently. For AUD pharmacotherapy: acamprosate (renal clearance) is generally preferred over naltrexone (hepatotoxicity concern). Behavioral support and engagement remain central.
Match the agent to the patient's liver function. The choices are usually available.